LINDAHL RICHARD S — SEC Form 4 filings
SEC reporting owner CIK 1196632. 18 Form 4 filings on record with FilingPulse; latest filed 2026-06-10.
Transaction summary — filings shown
Covers all 18 filings on record, filed 2024-02-14 to 2026-06-10. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 26.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | EVP, Chief Financial Officer | 15 | — | — | 23 |
| Compass Therapeutics, Inc. (CMPX) | Director | 3 | — | — | 3 |
Form 4 filings — LINDAHL RICHARD S
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-10 | 4 | Emergent BioSolutions Inc. (EBS) | Tax withholding (F): 3,964 @ $8 | EDGAR |
| 2026-05-01 | 4 | Emergent BioSolutions Inc. (EBS) | Grant/award (A): 162,680 @ $0 | EDGAR |
| 2026-03-06 | 4 | Emergent BioSolutions Inc. (EBS) | Code (H): 19,963 (derivative) @ $0 · Code (H): 20,321 (derivative) @ $0 | EDGAR |
| 2026-03-05 | 4 | Emergent BioSolutions Inc. (EBS) | Tax withholding (F): 23,650 @ $8.44 · Grant/award (A): 72,856 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Emergent BioSolutions Inc. (EBS) | Tax withholding (F): 683 @ $8.15 | EDGAR |
| 2026-02-10 | 4 | Emergent BioSolutions Inc. (EBS) | Disposition to issuer (D): 46,155 @ $10.92 · Tax withholding (F): 5,642 @ $10.92 | EDGAR |
| 2026-01-05 | 4 | Compass Therapeutics, Inc. (CMPX) | Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2025-10-17 | 4 | Emergent BioSolutions Inc. (EBS) | Tax withholding (F): 4,995 @ $9.60 | EDGAR |
| 2025-06-10 | 4 | Emergent BioSolutions Inc. (EBS) | Tax withholding (F): 2,733 @ $6.63 | EDGAR |
| 2025-03-10 | 4 | Emergent BioSolutions Inc. (EBS) | Grant/award (A): 146,888 @ $0 · Grant/award (A): 178,546 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | Emergent BioSolutions Inc. (EBS) | Disposition to issuer (D): 16,916 @ $0 · Tax withholding (F): 1,073 @ $7.48 · Tax withholding (F): 683 @ $7.48 | EDGAR |
| 2025-02-13 | 4 | Compass Therapeutics, Inc. (CMPX) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2024-10-17 | 4 | Emergent BioSolutions Inc. (EBS) | Grant/award (A): 15,000 @ $0 | EDGAR |
| 2024-06-11 | 4 | Emergent BioSolutions Inc. (EBS) | Tax withholding (F): 2,733 @ $6.19 | EDGAR |
| 2024-03-15 | 4 | Emergent BioSolutions Inc. (EBS) | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2024-03-04 | 4 | Emergent BioSolutions Inc. (EBS) | Tax withholding (F): 9,037 @ $3.23 · Tax withholding (F): 684 @ $3.39 | EDGAR |
| 2024-02-27 | 4 | Emergent BioSolutions Inc. (EBS) | Disposition to issuer (D): 4,012 @ $2.71 · Tax withholding (F): 517 @ $2.74 | EDGAR |
| 2024-02-14 | 4 | Compass Therapeutics, Inc. (CMPX) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1196632 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →